In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen
dc.contributor.author | Langguth, Peter | en_US |
dc.contributor.author | Marroum, Patrick | en_US |
dc.date.accessioned | 2012-11-07T17:04:33Z | |
dc.date.available | 2013-11-15T16:44:23Z | en_US |
dc.date.issued | 2012-10 | en_US |
dc.identifier.citation | Langguth, Peter; Marroum, Patrick (2012). " In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen." Biopharmaceutics & Drug Disposition 33(7): 366-377. <http://hdl.handle.net/2027.42/94252> | en_US |
dc.identifier.issn | 0142-2782 | en_US |
dc.identifier.issn | 1099-081X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/94252 | |
dc.description.abstract | The FDA Biopharmaceutical Classification System guidance allows waivers for in vivo bioavailability and bioequivalence studies for immediate‐release solid oral dosage forms only for BCS class I. Extensions of the in vivo biowaiver for a number of drugs in BCS class III and BCS class II have been proposed, in particular, BCS class II weak acids. However, a discrepancy between the in vivo BE results and in vitro dissolution results for BCS class II acids was recently observed. The objectives of this study were to determine the oral absorption of BCS class II weak acids via simulation software and to determine if the in vitro dissolution test with various dissolution media could be sufficient for in vitro bioequivalence studies of ibuprofen and ketoprofen as models of carboxylic acid drugs. The oral absorption of these BCS class II acids from the gastrointestinal tract was predicted by GastroPlus™. Ibuprofen did not satisfy the bioequivalence criteria at lower settings of intestinal pH of 6.0. Further the experimental dissolution of ibuprofen tablets in a low concentration phosphate buffer at pH 6.0 (the average buffer capacity 2.2 mmol l ‐1 /pH) was dramatically reduced compared with the dissolution in SIF (the average buffer capacity 12.6 mmol l ‐1 /pH). Thus these predictions for the oral absorption of BCS class II acids indicate that the absorption patterns depend largely on the intestinal pH and buffer strength and must be considered carefully for a bioequivalence test. Simulation software may be a very useful tool to aid the selection of dissolution media that may be useful in setting an in vitro bioequivalence dissolution standard. Copyright © 2012 John Wiley & Sons, Ltd. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Dissolution Media | en_US |
dc.subject.other | Simulation | en_US |
dc.subject.other | GastroPlus | en_US |
dc.subject.other | Weak Acid | en_US |
dc.subject.other | Ibuprofen | en_US |
dc.subject.other | Ketoprofen | en_US |
dc.subject.other | In Vitro Dissolution | en_US |
dc.subject.other | PH | en_US |
dc.title | In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 22815122 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/94252/1/bdd1800.pdf | |
dc.identifier.doi | 10.1002/bdd.1800 | en_US |
dc.identifier.source | Biopharmaceutics & Drug Disposition | en_US |
dc.identifier.citedreference | Kortejarvi H, Shawahna R, Koski A, et al. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs. J Pharm Sci 2010; 99: 621 – 625. | en_US |
dc.identifier.citedreference | Mutalik S, Anju P, Manoj K, et al. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan‐based solvent change approach. Int J Pharm 2008; 350: 279 – 290. | en_US |
dc.identifier.citedreference | US FDA Waiver of in vivo bioavailability and bioequivalence studies for immediate‐release solid oral dosage forms based on a Biopharmaceutics Classification System. FDA Guidance for Industry, 2002. | en_US |
dc.identifier.citedreference | EMA Concept Paper on BCS‐ Based Biowaiver, 2007. | en_US |
dc.identifier.citedreference | Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921 – 925. | en_US |
dc.identifier.citedreference | Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101 – 154. | en_US |
dc.identifier.citedreference | Dressman JB, Hempenstall J, Reppas C. The BCS: Where do we go from here? Pharm Technol 2001; 25: 68 – 76. | en_US |
dc.identifier.citedreference | Aburub A, Risley DS, Mishra D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int J Pharm 2008; 347: 16 – 22. | en_US |
dc.identifier.citedreference | Ghosh LK, Ghosh NC, Chatterjee M, et al. Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Drug Dev Ind Pharm 1998; 24: 473 – 477. | en_US |
dc.identifier.citedreference | Kaus LC, Fell JT. Effect of stress on the gastric emptying of capsules. J Clin Hosp Pharm 1984; 9: 249 – 251. | en_US |
dc.identifier.citedreference | Oberle RL, Chen TS, Lloyd C, et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990; 99: 1275 – 1282. | en_US |
dc.identifier.citedreference | Ibekwe VC, Fadda HM, McConnell EL, et al. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo‐colonic release systems. Pharm Res 2008; 25: 1828 – 1835. | en_US |
dc.identifier.citedreference | Madsen JL, Krogsgaard OW. Gastrointestinal scintiscanning: dosimetry. Eur J Nucl Med 1989; 15: 260 – 261. | en_US |
dc.identifier.citedreference | Lee KJ, Vos R, Janssens J, et al. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol 2004; 286: G278 – G284. | en_US |
dc.identifier.citedreference | Perez de la Cruz Moreno M, Oth M, Deferme S, et al. Characterization of fasted‐state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079 – 1089. | en_US |
dc.identifier.citedreference | Kalantzi L, Goumas K, Kalioras V, et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23: 165 – 176. | en_US |
dc.identifier.citedreference | Persson EM, Gustafsson AS, Carlsson AS, et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22: 2141 – 2151. | en_US |
dc.identifier.citedreference | Corrigan OI, Devlin Y, Butler J. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro‐in vivo correlation. Int J Pharm 2003; 254: 147 – 154. | en_US |
dc.identifier.citedreference | Levis KA, Lane ME, Corrigan OI. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm 2003; 253: 49 – 59. | en_US |
dc.identifier.citedreference | Galia E, Nicolaides E, Horter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698 – 705. | en_US |
dc.identifier.citedreference | Jantratid E, Janssen N, Reppas C, et al. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663 – 1676. | en_US |
dc.identifier.citedreference | Karr WG, Abbott WO, Sample AB. Intubation studies of the human small intestine. IV. Chemical characteristics of the intestinal contents in the fasting state and as influenced by the administration of acids, of alkalies and of water. J Clin Invest 1935; 14: 893 – 900. | en_US |
dc.identifier.citedreference | Anand O, Yu LX, Conner DP, et al. Dissolution testing for generic drugs: an FDA perspective. AAPS J 2011; 13: 328 – 335. | en_US |
dc.identifier.citedreference | Siewert M, Dressman J, Brown CK, et al. FIP/AAPS guidelines to dissolution/ in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2003; 4: E7. | en_US |
dc.identifier.citedreference | U.S. FDA Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research. Guidances for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate‐release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000. | en_US |
dc.identifier.citedreference | EMA Guideline on the Investigation of Bioequivalence, 2010. | en_US |
dc.identifier.citedreference | Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413 – 420. | en_US |
dc.identifier.citedreference | Yazdanian M, Briggs K, Jankovsky C, et al. The ‘high solubility’ definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004; 21: 293 – 299. | en_US |
dc.identifier.citedreference | Gupta E, Barends DM, Yamashita E, et al. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci 2006; 29: 315 – 324. | en_US |
dc.identifier.citedreference | Polli JE, Abrahamsson BS, Yu LX, et al. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J 2008; 10: 373 – 379. | en_US |
dc.identifier.citedreference | Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 2005; 26: 321 – 334. | en_US |
dc.identifier.citedreference | Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28: 100 – 114. | en_US |
dc.identifier.citedreference | Faassen F, Vromans H. Biowaivers for oral immediate‐release products: implications of linear pharmacokinetics. Clin Pharmacokinet 2004; 43: 1117 – 1126. | en_US |
dc.identifier.citedreference | Kovacevic I, Parojcic J, Homsek I, et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2008; 6: 40 – 47. | en_US |
dc.identifier.citedreference | Tubic‐Grozdanis M, Bolger MB, Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J 2008; 10: 213 – 226. | en_US |
dc.identifier.citedreference | Potthast H, Dressman JB, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci 2005; 94: 2121 – 2131. | en_US |
dc.identifier.citedreference | Alvarez C, Nunez I, Torrado JJ, et al. Investigation on the possibility of biowaivers for ibuprofen. J Pharm Sci 2011; 100: 2343 – 2349. | en_US |
dc.identifier.citedreference | Mooney KG, Mintun MA, Himmelstein KJ, et al. Dissolution kinetics of carboxylic acids II: effect of buffers. J Pharm Sci 1981; 70: 22 – 32. | en_US |
dc.identifier.citedreference | Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999; 46: 183 – 196. | en_US |
dc.identifier.citedreference | Vertzoni M, Fotaki N, Kostewicz E, et al. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol 2004; 56: 453 – 462. | en_US |
dc.identifier.citedreference | The United States Pharmacopeia. USP 24 The National Formulary NF19, 2000. | en_US |
dc.identifier.citedreference | Sheng JJ, McNamara DP, Amidon GL. Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm 2009; 6: 29 – 39. | en_US |
dc.identifier.citedreference | Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum 1985; 28: 1117 – 1121. | en_US |
dc.identifier.citedreference | Avdeef A, Box KJ, Comer JE, et al. pH‐metric log P 11. pKa determination of water‐insoluble drugs in organic solvent‐water mixtures. J Pharm Biomed Anal 1999; 20: 631 – 641. | en_US |
dc.identifier.citedreference | Avdeef A, Box KJ, Comer JE, et al. pH‐metric logP 10. Determination of liposomal membrane‐water partition coefficients of ionizable drugs. Pharm Res 1998; 15: 209 – 215. | en_US |
dc.identifier.citedreference | Geisslinger G, Menzel S, Wissel K, et al. Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. Br J Clin Pharmacol 1995; 40: 73 – 75. | en_US |
dc.identifier.citedreference | Herzfeldt CD, Kummel R. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal antiinflammatories. Drug Dev Ind Pharm 1983; 9: 767 – 793. | en_US |
dc.identifier.citedreference | Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85 – 96. | en_US |
dc.identifier.citedreference | Sangster J. Octanol‐water partition coefficients, 1993. | en_US |
dc.identifier.citedreference | Lu AT, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res 1993; 10: 1308 – 1314. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.